Adamed teams up with BioCentrum to develop innovative oncological drug

02-Dec-2009 - Poland

Adamed and BioCentrum announced launch of a new research project, which may have a significant impact on the development of the Polish pharmaceutical sector. The aim of this joint project is to develop an innovative oncology drug.

The initial phase of research involves mainly identification and structural characterization of new molecules, inhibitors of one of the major pathways of proteins involved in the process of oncogenesis. The second phase of the project will involve Adamed performing clinical trials of the potential drug.

Research will be mainly based on the use of latest-generation analytical methods. Tasks scheduled include advanced computationally-aided compound development supported by calculations, method development for the synthesis of chemically isolated compounds, an innovative process of in vitro screening of compounds with advanced biochemical assays, lead optimization using computational methods, crystallography and animal studies.

The final outcome of this project has a chance to become the first cancer therapy in the world which uses this particular protein target. Potentially, as many as three million patients worldwide would be able to benefit from this treatment. It is presumed that the phase I clinical trials could begin in 2013.

https://www.bionity.com/en/news/110231/adamed-teams-up-with-biocentrum-to-develop-innovative-oncological-drug.html